Perifosine是一种具有口服活性的烷基磷酸胆碱 Akt 抑制剂,具有抗肿瘤活性。
产品描述
Perifosine is an oral-active, alkyl-phosphocholine Akt inhibitor with potential antineoplastic activity.
体外活性
在神经胶质瘤中,Perifosine激活Akt和Ras-ERK1/2途径.Perifosine诱导血小板和白细胞增多,导致移植骨髓瘤的凋亡.
体内活性
在MM.1S细胞中,Perifosine(10 μM )能够完全抑制Akt的磷酸化。在永生化角质形成细胞和头颈部鳞状癌细胞中(IC50=0.6-8.9 μM),Perifosine抑制细胞增殖。在小鼠的神经胶质祖细胞中,Perifosine通过减少Akt的磷酸化水平和细胞外信号调节激酶,诱导细胞周期停滞在G1和G2,引起细胞生长抑制。在人类肝癌细胞中,Perifosine通过阻断Akt的磷酸化,诱导细胞周期停滞和细胞凋亡。
激酶实验
Akt kinase assay: MM.1S cells are cultured in the presence or absence of perifosine (5 μM, 6 hours) and then stimulated with IL-6 (20 ng/mL, 10 minutes). In vitro akt kinase assay is then carried out using the Akt Kinase Assay Kit.
细胞实验
Cells are incubated in the medium with 10% FCS for 48 hours with indicated concentration of Periosine. Cell viability is determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. (Cell Proliferation Kit I; Roche). The absorbance at 590 nm is recorded using the 96-well plate reader.(Only for Reference)
Cas No.
157716-52-4
分子式
C25H52NO4P
分子量
461.668
别名
D21266;NSC 639966;哌立福新;KRX-0401
储存和溶解度
DMSO:Insoluble
H2O:10 mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years